System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 25 citations

PubMed: 39114362 DOI: 10.3389/fphar.2024.1424606

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.

Front Pharmacol 15:1424606

Authors: Zhen Zeng, Hao Lin, Mingshan Jiang, Jing Yuan, Xi Li, Yongbin Jia, Li Yang, Hu Zhang

Affiliations

  • Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. Centre for Inflammatory Bowel Disease, West China Hospital, Sichuan University, Chengdu, China. Lab of Inflammatory Bowel Disease, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
  • Centre for Inflammatory Bowel Disease, West China Hospital, Sichuan University, Chengdu, China.
  • Lab of Inflammatory Bowel Disease, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
  • Lab of Inflammatory Bowel Disease, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs. The recent expiration of patents of some anti-TNFα biologics (such as infliximab and adalimumab) facilitated the development of biosimilars. Comparable pharmacokinetic, efficacy, safety, and immunogenicity profiles between anti-TNFα originators and biosimilars were demonstrated in different studies. Anti-TNFα biosimilars hold promise for reducing the high cost of biologics and increasing patient access to biologics. In this review, we outline the current data on the use of anti-TNFα originators and biosimilars in patients with IBD, with a focus on the efficacy, safety, and immunogenicity profiles of infliximab and adalimumab biosimilars. The potential benefits, challenges, and future directions of anti-TNFα biosimilars are also discussed in the review.

MeSH

Safety, Inflammatory Bowel Diseases, Adalimumab, Infliximab, Biosimilar Pharmaceuticals

Cited by